Iterum Therapeutics plc

ITRMSEC EDGAR

Pharmaceutical Preparations(L2)CIK: 1659323

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$37.0K	$869.0K
Research and Development Expense	$17.6M	$10.7M	$21.1M	$90.8M	$68.6M
Operating Expenses	$30.4M	$24.5M	$32.1M	$102.1M	$77.4M
Operating Income (Loss)	-$30.4M	-$24.5M	-$32.1M	-$102.0M	-$76.6M
Nonoperating Income (Expense)	-$13.8M	-$66.3M	-$19.1M	-$665.0K	-$25.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$44.1M	-$90.9M	-$51.3M	-$102.7M	-$76.6M
Income Tax Expense (Benefit)	$301.0K	$705.0K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$26.3M	$66.8M	$91.5M	$32.8M	$25.8M
Assets, Current	$25.6M	$62.4M	$83.3M	$21.5M	$11.7M
Cash and Cash Equivalents, at Carrying Value	$6.1M	$21.1M	$27.4M	$14.5M	$4.8M
Inventory, Net	$0.00	$0.00	$0.00	$0.00	$0.00
Liabilities	$32.7M	$38.8M	$41.3M	$83.4M	$52.0M
Liabilities, Current	$13.5M	$9.1M	$12.9M	$41.7M	$37.0M
Long-term Debt	$31.2M	$11.2M	$12.7M	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$18.5M	-$15.8M	-$54.5M	-$81.9M	-$77.3M
Net Cash Provided by (Used in) Investing Activities	$14.0M	-$54.6M	-$11.0K	$40.1M	-$8.7M
Net Cash Provided by (Used in) Financing Activities	-$1.8M	$83.1M	$64.5M	$2.1M	$122.2M
Payments to Acquire Property, Plant, and Equipment	$62.0K	$61.0K	$11.0K	$24.0K	$90.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)